by ASTCT Talks
In the next installment of ASTCT's Titans of Transplant series, Dr. Shernan Holtan sits down with Dr. Daniel Weisdorf—renowned leader, mentor and pioneer in cellular therapy and...
by David Porter, MD
In this month's President’s Message, Dr. David Porter shares his perspective on the recent dismissal of the CDC’s vaccine advisory committee—and why it matters.
by Alex Kadhim
Researchers from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) conducted the PHYLOS trial and found that posttransplant cyclophosphamide (PTCy)-based prophylaxis significantly reduces the...
by ASTCT Talks
An expert panel highlights key presentations in multiplemyeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.
CancerNetwork®, in collaboration with The...
by Alex Kadhim
Researchers from the National Cancer Institute (NCI), USA, have demonstrated that intermediate-dose post-transplantation cyclophosphamide (ID-PTCy) at 25 mg/kg/day administered on days 3 and 4...
by Alex Kadhim
Researchers from Stanford University have demonstrated that administering precision-selected donor regulatory T-cell (Treg) therapy significantly improves graft-versus-host disease-free,...